NO20052009L - Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom - Google Patents

Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom

Info

Publication number
NO20052009L
NO20052009L NO20052009A NO20052009A NO20052009L NO 20052009 L NO20052009 L NO 20052009L NO 20052009 A NO20052009 A NO 20052009A NO 20052009 A NO20052009 A NO 20052009A NO 20052009 L NO20052009 L NO 20052009L
Authority
NO
Norway
Prior art keywords
treatment
myelodysplastic syndrome
acute leukemia
combination therapy
pharmaceutical combinations
Prior art date
Application number
NO20052009A
Other languages
English (en)
Other versions
NO20052009D0 (no
Inventor
Jay Marshall Feingold
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20052009D0 publication Critical patent/NO20052009D0/no
Publication of NO20052009L publication Critical patent/NO20052009L/no

Links

Classifications

    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices
    • E05F3/04—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes
    • E05F3/10—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction
    • E05F3/108—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices with liquid piston brakes with a spring, other than a torsion spring, and a piston, the axes of which are the same or lie in the same direction with piston rod protruding from the closer housing; Telescoping closers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • E—FIXED CONSTRUCTIONS
    • E05—LOCKS; KEYS; WINDOW OR DOOR FITTINGS; SAFES
    • E05F—DEVICES FOR MOVING WINGS INTO OPEN OR CLOSED POSITION; CHECKS FOR WINGS; WING FITTINGS NOT OTHERWISE PROVIDED FOR, CONCERNED WITH THE FUNCTIONING OF THE WING
    • E05F3/00—Closers or openers with braking devices, e.g. checks; Construction of pneumatic or liquid braking devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives fremgangsmåter for behandling og farmasøytiske kombinasjoner for behandlingen av akutt leukemi, så som akutt myelogen leukemi og myelodysplastisk syndrom. Fremgangsmåtene og de farmasøytiske kombinasjonene benytter et anti-CD33 cytotoksisk konjugat i kombinasjon med minst én forbindelse valgt fra gruppen bestående av et antracyklin og en pyrimidin- eller purin-nukleosidanalog. Foretrukne fremgangsmåter for behandling og farmasøytiske kombinasjoner benytter gemtuzumab ozogamicin, daunorubicin og cytarabin.
NO20052009A 2002-11-06 2005-04-25 Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom NO20052009L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2002/035532 WO2004043461A1 (en) 2002-11-06 2002-11-06 Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome

Publications (2)

Publication Number Publication Date
NO20052009D0 NO20052009D0 (no) 2005-04-25
NO20052009L true NO20052009L (no) 2005-06-27

Family

ID=32311637

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052009A NO20052009L (no) 2002-11-06 2005-04-25 Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom

Country Status (10)

Country Link
EP (1) EP1575582A4 (no)
JP (1) JP2006508119A (no)
CN (1) CN1720044A (no)
AU (2) AU2002348178A1 (no)
BR (1) BR0215935A (no)
CA (1) CA2504611A1 (no)
CR (1) CR7804A (no)
MX (1) MXPA05004711A (no)
NO (1) NO20052009L (no)
WO (1) WO2004043461A1 (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
EP1661584A1 (en) * 2004-11-26 2006-05-31 Heinz Dr. Faulstich Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
KR20080030659A (ko) * 2005-07-06 2008-04-04 카니사 파마슈티컬즈, 인크. 칼리키아미신-항체 컨쥬게이트를 조스퀴다르와 조합하여사용하는 암 환자의 치료
ES2371085T3 (es) * 2006-05-27 2011-12-27 Faulstich, Heinz, Dr. Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
CN1994293A (zh) * 2006-08-18 2007-07-11 上海交通大学医学院附属瑞金医院 冬凌草甲素在制药中的应用
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
PL3300601T3 (pl) * 2007-02-16 2022-05-02 Rotalec Ip Holdings Llc Ustalone stosunki leków do leczenia nowotworów hematopoetycznych i zaburzeń proliferacyjnych
EP2249831A2 (en) * 2007-12-10 2010-11-17 Sunesis Pharmaceuticals, Inc. Methods of using (+)-1,4-dihydro-7-ý(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl¨-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
US20110159507A1 (en) 2008-08-29 2011-06-30 School Juridical Person The Kitasato Institute Method for detecting the drug effects of dna methylation-inhibitors
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
WO2017210621A1 (en) * 2016-06-03 2017-12-07 Seattle Genetics, Inc. Combination of cd33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
AR112202A1 (es) * 2017-06-22 2019-10-02 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cánceres hematológico, usos y composiciones farmacéuticas de esta
CA3069558A1 (en) * 2017-07-09 2019-01-17 Biosight Ltd. Combination cancer therapy
IL285155B2 (en) * 2019-01-28 2026-01-01 Univ Texas Therapy using metal chelators to treat cancer
CN110123825B (zh) * 2019-05-28 2021-11-30 宁波市鄞州人民医院 一种包含去甲氧柔红霉素的药物组合物
WO2022093983A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma, Inc. Compositions and methods for treating hematopoietic malignancy
WO2025214401A1 (zh) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 抗体药物偶联物、组合物及其用途和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
CA2418014C (en) * 2000-08-08 2014-01-21 Immunomedics, Inc. Immunotherapy for chronic myelocytic leukemia

Also Published As

Publication number Publication date
WO2004043461A1 (en) 2004-05-27
NO20052009D0 (no) 2005-04-25
CN1720044A (zh) 2006-01-11
CR7804A (es) 2008-10-29
CA2504611A1 (en) 2004-05-27
AU2002348178A1 (en) 2004-06-03
BR0215935A (pt) 2005-08-09
EP1575582A4 (en) 2009-03-11
EP1575582A1 (en) 2005-09-21
MXPA05004711A (es) 2005-08-03
AU2010201113A1 (en) 2010-04-15
JP2006508119A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
NO20052009L (no) Kombinasjonsterapi for behandling av akutt leukumi og myelodysplastikksyndrom
WO2007022073A3 (en) Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
NZ543867A (en) Modified fluorinated nucleoside analogues
CY1113012T1 (el) Λιποσωμικες φαρμακοτεχνικες μορφες παραγοντων ανθρακυκλινης και αναλογων κυτιδινης
AP2005003211A0 (en) 1'-,2'-and 3'-modified nucleoside derivatives for treating flaviviridae infections.
UY29949A1 (es) Composición farmacéutica con edulcorante de alta intensidad
ES2138969T3 (es) Combinacion de nucleosidos antivirales.
BRPI9809791B8 (pt) compostos imuno efetores de fosfato de aminoalquil glucosamina e composições compreendendo os mesmos
DK0526537T3 (da) 5-Benzylbarbituratderivater
PL1644392T3 (pl) Węglowodanowe pochodne rapamycyny
UY29954A1 (es) Composicion edulcorante de alta intensidad con un agente antiinflamatorio y composiciones endulzadas con ella
DK1412368T3 (da) Sukkerderivater af hydromorfon, dihydromorfin, dihydroisomorfin, sammensætninger deraf og anvendelser til behandling eller forebyggelse af smerter
RS20120201A3 (en) Methods and compositions for hepatitis c virus treatment
MX2009012155A (es) Combinación farmacéutica sinérgica para el tratamiento de cáncer.
BRPI0503981A (pt) substituto do açúcar apetecìvel, de baixa caloria com agente de volume insolúvel em água
WO2004028475A3 (en) Glycosylceramide analogues
PT1368041E (pt) Composicao aquosa de anfotericina
BR9908391A (pt) Composição antitumural contendo uma combinação sinergìstica de um derivado de antraciclina com um derivado de camptotecina
WO2008104893A3 (en) Nucleoside derivatives useful for the treatment or prevention of viral infections and methods of use thereof
DK1079840T3 (da) Synergistisk præparat af inulin og et anticancerlægemiddel til anvendelse til behandling af cancer
HRP20090336T1 (hr) Antitumorske kombinacije koje sadrže zamku za vegf i 5-fu ili jedan od njegovih derivata
UA83204C2 (ru) Комбинированная терапия для лечения острого лейкоза и миелодиспластичного синдрома
EP4464701A4 (en) 1,3-BENZODIOXOLE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING IT
ATE465741T1 (de) 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität
RU2005117335A (ru) Комбинированная терапия для лечения острого лейкоза и миелодиспластического синдрома

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application